Clinical Trial Update: Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study of lurbinectedin in combination with paclitaxel, with or without bevacizumab, in selected advanced solid tumors (completed; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gynecological Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Non-squamous Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lurbinectedin (lurbinectedin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: PharmaMar | Conditions: Breast Cancer, Ovarian Cancer | Phase 1 | Status: COMPLETED | Results posted: 2020-03-20